In these publications, AAbs to six tumor-associated antigens (p53, NY-ESO-1, Annexin I, CAGE, GBU4-5, and SOX2) were measured and identified up to 40 % of all lung cancers in the disease groups, with a specificity of 90 % (non-cancer controls individually matched to lung cancer sera by age, gender, and smoking history) [1, 10]. This evidence concerns the gene DDX53 and lung carcinoma.